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a b s t r a c t
This study was conducted to investigate whether augmentation of macular pigment (MP) enhances visual
performance (VP). 121 normal subjects were recruited. The active (A) group consumed 12 mg of lutein (L)
and 1 mg of zeaxanthin (Z) daily. MP optical density (MPOD) was assessed by customized heterochro-
matic flicker photometry. VP was assessed as best corrected visual acuity (BCVA), mesopic and photopic
contrast sensitivity (CS), glare disability, photostress, and subjective visual function. Subjects were
assessed at baseline; 3; 6; 12 months (V1, V2, V3 and V4, respectively). Central MPOD increased signif-
icantly in the A group (p < 0.05) but not in the placebo group (p > 0.05). This statistically significant
increase in MPOD in the A group was not, in general, associated with a corresponding improvement in
VP (p > 0.05, for all variables), with the exception of a statistically significant time/treatment effect in
‘‘daily tasks comparative analysis’’ (p = 0.03). At V4, we report statistically significant differences in meso-
pic CS at 20.7 cpd, mesopic CS at 1.5 cpd under high glare conditions, and light/dark adaptation compar-
ative analysis between the lower and the upper MP tertile groups (p < 0.05) Further study into the
relationship between MP and VP is warranted, with particular attention directed towards individuals
with low MP and suboptimal VP.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
The dietary carotenoids zeaxanthin (Z) and lutein (L) and L’s ret-
inal isomer meso-zeaxanthin (meso-Z) are lipid-like molecules that
accumulate at the macula, where they are collectively referred to
as macular pigment (MP) (Bone, Landrum, Hime, Cains, & Zamor,
1993). An average western diet contains about 1.3–3 mg/day of L
and Z combined (Nebeling, Forman, Graubard, & Snyder, 1997a,
1997b), with significantly more L than Z (represented by an esti-
mated ratio of 7:1). Approximately 78% of dietary L and Z is
sourced from vegetables (Sommerburg, Keunen, Bird, & van Kuijk,
1998). L is found in highest concentrations in dark green leafy veg-
etables, such as spinach, kale, and collard greens (Sommerburg
et al., 1998). Z is the major carotenoid found in orange peppers,
and oranges, with a high mole percentage of both L and Z being
found in egg yolk (Sommerburg et al., 1998), with comparable
amounts of L and Z recently reported in corn and a variety of corn
containing products (e.g. cornmeal and cereal) (Perry, Rasmussen,
& Johnson, 2009). Possible dietary sources of meso-Z include
shrimp, certain marine fish, and turtles, none of which are found
in a typical western diet (Maoka, Arai, Shimizu, & Matsuno,
1986), however, it has recently been suggested that MZ may be
present in some other, yet to be identified, foods (Connolly et al.,
2010).
The macula is a specialized part of the retina, as it mediates cen-
tral vision, provides sharpest visual acuity, and facilities best color
discrimination (Hirsch & Curcio, 1989). Age-related macular
degeneration (AMD) is a disease of the macula and results in the
loss of central and color vision. AMD is the most common cause
of blindness in the elderly population in the developed world
(Congdon et al., 2004). It is now understood that oxidative stress
(Beatty, Koh, Henson, & Boulton, 2000; Winkler, Boulton, Gottsch,
& Sternberg, 1999), exacerbated in part by cumulative short-
wavelength visible light exposure (Algvere, Marshall, & Seregard,
2006; Fletcher et al., 2008), is important in the aetiopathogenesis
of AMD. MP is a short-wavelength (blue) light filter (Bone,
Landrum, & Cains, 1992) and a powerful antioxidant (Khachik,
Bernstein, & Garland, 1997), and is therefore believed to protect
against AMD (Loane, Kelliher, Beatty, & Nolan, 2008). This
hypothesis, referred to as the ‘‘protective’’ hypothesis of MP, has
been studied and reported on extensively (Loane et al., 2008).
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Beyond its ‘‘protective’’ hypothesis, MP’s optical and anatomic
properties have prompted the ‘‘optical’’ hypotheses of this pigment.
The ‘‘optical’’ hypotheses of MP have been previously discussed by
Reading andWeale (1974) and later byNussbaum,Pruett, andDelori
(1981), and include MP’s putative ability to enhance visual perfor-
mance and/or comfort by attenuation of the effects of chromatic
aberration and light scatter, via its shortwave light-filtering proper-
ties (Walls & Judd, 1933). This traditional description of the ‘‘optical
hypothesis’’ does not account for additional mechanisms whereby
MP may enhance visual performance, that are, perhaps, unrelated
to the short wave filtration properties of MP. MP has been shown
to exhibit dichroic properties (Hemenger, 1982) which may facili-
tate the reduction of glare disability through preferential absorption
of polarized light. HigherMPODhas also been observed to relate to a
trend towards lower root-mean-square wavefront aberrations (in
particular, higher order aberrations), thereby enhancing visual per-
formance (Kvansakul et al., 2006).
There is one additional, and important, mechanism, whereby
MP may have a beneficial effect on visual performance and experi-
ence. The antioxidant properties of the MP carotenoids may atten-
uate or prevent the deleterious effects of free radical damage on
the physiological functions of the photoreceptors and their axons.
Many studies (to date mostly cross-sectional in design) have
evaluated, and reported on the role of MP in visual performance,
including: visual acuity; contrast sensitivity; glare disability; pho-
tostress recovery; critical flicker fusion frequency (CFF); color vi-
sion (amongst others) (Bartlett & Eperjesi, 2008; Engles, Wooten,
& Hammond, 2007; Hammond & Wooten, 2005; Kvansakul et al.,
2006; Loughman et al., 2010; Rodriguez-Carmona et al., 2006;
Stringham, Fuld, & Wenzel, 2004; Stringham & Hammond, 2007,
2008; Wooten & Hammond, 2002). However, a placebo-controlled,
randomized, L-based supplementation trial was needed to investi-
gate if augmentation of MPOD actually enhances visual perfor-
mance and/or comfort. The Collaborative Optical Macular
Pigment ASsessment Study (COMPASS), presented here, was de-
signed specifically to answer this important research question.
2. Methods
2.1. Subjects and study sites
COMPASS was conducted at Waterford Institute of Technology
(WIT) and Dublin Institute of Technology (DIT), vision science labo-
ratories, located in the southeast and east of the Republic of Ireland,
respectively. One hundred and twenty-one healthy subjects
volunteered to participate in this two-centered study, which was
approved by the research ethics committees at both study sites.
Self-selected recruitment of subjects (WIT: n = 61 and DIT: n = 60)
was facilitated by poster and newsletter advertisement, and also
by word of mouth, in the respective local communities. Informed
consent was obtained from each volunteer, and the experimental
procedures adhered to the tenets of the Declaration of Helsinki.
All subjects were aged between 18 to 41 years, in perfect gen-
eral (self report) and ocular health (see below), and with visual
acuity of at least 20/30 in the study eye. A typical study visit lasted
approximately 4 h. Subjects were assessed at baseline, three, six,
and 12 months (V1, V2, V3 and V4, respectively). All subjects re-
cruited into the study were classed as naïve observers to the tests
carried out (with the exception of the visual acuity test, with which
all subjects were familiar). However, to optimize performance, and
also to minimize any potential learning effects on performance, all
subjects underwent a defined period of pre-test training. This
training consisted of careful explanation of the nature of each test,
pictorial and/or video demonstration of the test requirements and
procedure, and was followed by a defined session of pre-test
practice.
2.2. Study design and formulation
COMPASS is a registered trial on the ISRCTN database (number
35481392), and is a randomized placebo-controlled clinical trial of
oral supplementation with a formulation containing the macular
carotenoids (L andZ)andco-antioxidantsversusplacebo.The tablets
used in the current study were hard film coated tablets. The daily
dose of two tablets for the active (A) group consisted of 12 mg
L, 1 mg Z (provided as ester), 120 mg vitamin C, 17.6 mg vitamin
E, 10 mg zinc and 40 lg selenium. The placebo (P) consisted of cellu-
lose, lactose and magnesium stearate, and was manufactured to be
identical to the A preparation in terms of size and color. The study
tablets for the A and P groups were packaged into identical blister
packs which contained the subjects’ anonymized unique identifica-
tion number and COMPASS study label information. Subjects were
instructed to consume the daily dose of two tablets with a meal.
Compliance was assessed by tablet counting at each study visit,
and encouraged by frequent reminder telephone calls and text
messages by the study COMPASS research team. Compliance was
also assessed at the end of the study by quantifying L and Z concen-
trations in serum, at each study visit, using high performance li-
quid chromatography (HPLC).
2.3. Demographic, medical history, lifestyle and vision case history
questionnaires
The following details were recorded, for each volunteer, on a
purpose designed case report form: demographics; general health
status; smoking habits (never, current or past); alcohol consump-
tion (average unit weekly intake); exercise (minutes per week);
body mass index (BMI, kg/m2); blood pressure; ethnicity; marital
status; education; occupation.
A vision case history was also performed, and details reported
included: time since last eye examination; spectacles or contact
lens use; history of ocular treatment or surgery; history of occlu-
sion therapy or visual training in childhood; family history of eye
disease; current problems with vision; asthenopia associated with
computer use; history of headaches.
2.4. Diet and serum concentrations of lutein and zeaxanthin
Dietary intakes of L and Z were quantified using a self-adminis-
trated, semiquantitative food frequency questionnaire developed
by the Scottish Collaborative Group at the University of Aberdeen
(Scotland UK), recently described by O’Connell et al. (O’Connell
et al. 2008) Serum concentrations of L and Z were quantified by
HPLC using an assay previously reported by Loane et al.(Loane,
Nolan, & Beatty 2010).
2.5. Spectacle refraction, visual acuity, and ocular dominance
Each subject underwent precise spectacle refraction by an expe-
rienced optometrist to determine refractive error and best cor-
rected visual acuity (BCVA) for each eye. A computer generated
LogMAR test chart (Test Chart 2000 Pro; Thomson Software Solu-
tions) was used to determine BCVA at a viewing distance of 4 m,
using a Sloan ETDRS letterset. BCVA was determined as the average
of three measurements, with letter and line changes facilitated by
the software pseudo-randomization feature. Best corrected visual
acuity was recorded using a letter-scoring visual acuity rating, with
20/20 visual acuity assigned a value of 100. Best corrected visual
acuity was scored relative to this value, with each letter correctly
identified assigned a nominal value of one, so that, for example,
a BCVA of 20/20+1 equated to a score of 101, and 20/201 to 99.
The study eye was selected on the basis of ocular dominance,
determined using the Miles Test (Roth, Lora, & Heilman, 2002) with
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the dominant eye chosen as the study eye, except in cases of ob-
served equidominance, in which case the right eye was selected.
All subsequent tests were conducted with the subject’s optimal
subjective refraction in place.
2.6. Glare disability
Glare disability is a term used to describe the degradation of vi-
sual performance typically caused by loss of retinal image contrast.
Glare disability is often caused, for example, by surface light reflec-
tions, or bright light sources such as car headlights, and typically is
a consequence of increased forward light scatter within the eye.
Glare disability was assessed using a Functional Acuity Contrast
Test (FACT) (Hitchcock, Dick, & Krieg, 2004; Terzi, Buhren,
Wesemann, & Kohnen, 2005), displayed using the Functional
Vision Analyzer (Hohberger, Laemmer, Adler, Juenemann, & Horn,
2007) (Stereo Optical Co., Inc., Chicago, IL), which is a desktop
device that allows the measurement of contrast sensitivity, and
includes a customized internal glare source for assessing the
impact of glare on this measure of visual performance. The test
comprised linear, vertically oriented, sine wave gratings presented
at five different spatial frequencies including 1.5, 3, 6, 12 and 18
cycles per degree (cpd). Nine circular patches were presented at
each spatial frequency, the contrast of each patch decreasing by
0.15-log units from the previous. Gratings were tilted 15, 0 or
+15 with respect to the vertical, to keep them within the orienta-
tion bandwidth of the visual channel. The background was tapered
into a grey field in order to keep retinal illumination constant and
avoid ghost imaging. Baseline contrast sensitivity was determined
on the basis of the lowest contrast compatible with accurate deter-
mination of patch orientation across all five spatial frequencies for
mesopic [three candelas per meter squared (cdm2)] instrument
background conditions, initially in the absence of a glare source.
Subjects were asked to identify grating orientation, starting with
the patch at highest contrast, and continuing until identification
was no longer possible due to reducing contrast. Subjects were
instructed not to guess, but to respond ‘‘don’t know’’ if patch orien-
tation could not be correctly identified. As this procedure repre-
sented a non-standard psychophysical method of threshold
detection, each subject was required to re-identify the orientation
of certain gratings in a pseudo-random fashion in order to confirm
the validity of the subject responses at each spatial frequency.
Glare disability was assessed using a radial glare source consisting
of 12 white LEDs arranged circumferentially in an oval pattern sur-
rounding the grating charts (ranging from 4.5 to 6 from central
fixation). These LEDs have a color temperature of 6500 K, and the
spectral emission profile demonstrated a single large peak at
453 nm (close to MP peak absorption), where the spectral irradi-
ance was approximately double that of the peak emissions in the
flatter emission spectrum across mid to long wavelengths. Two
customized intensity settings were used to determine the effect
of different levels of glare on contrast sensitivity. Glare source set-
tings were set at a medium intensity of 42 Lux and a higher inten-
sity of 84 Lux. All correct responses were entered into the Eyeview
software provided, and contrast sensitivity scores for no glare,
medium and high glare conditions were determined for the respec-
tive spatial frequencies.
2.7. Visual Function in Normals questionnaire
A 30-part, non-validated, Visual Function in Normals question-
naire (VFNq30) was designed specifically for the study (JL). The de-
sign was based loosely on a previously validated visual activities
questionnaire (Sloane, Ball, Owsley, Bruni, & Roenker, 1992), but
adapted to suit a normal, young and healthy population sample.
This questionnaire allowed the subject to quantify their visual
performance using three separate metrics: situational analysis
(SA) which required the subject to rate their visual performance in
specified daily life situations; comparative analysis (CA) which re-
quired the subject to compare their perceived visual performance
to that of their peers/family/friends; subject satisfaction score
(SSS) which required the subject to provide an overall estimate of
their perceived quality of vision. Each of the three metrics above
was computed to give a performance score for five different func-
tional aspects of their vision: acuity/spatial vision; glare disability;
light/dark adaptation; daily visual tasks; color discrimination.
2.8. Contrast sensitivity function
A Dell Dimension 9200 computer and a Metropsis Visual Stim-
ulus Generation device (VSG (ViSaGe S/N: 81020197), Cambridge
Research Systems Ltd., Cambridge, UK) were used to generate
and control the stimuli. The VSG provided 14-bit output resolution
per phosphor. The stimuli were displayed on a 1900 ViewSonic pro-
fessional series p227f color CRT flat screen monitor with a frame
rate of 119.98 Hz. The resolution of the monitor was set to
1024  769 pixels. Non-linearities in the screen luminance output
were eliminated by gamma correction prior to testing using a
photometer system (Opti-Cal; Minolta, Japan). The Metropsis
software calculated the inverse curves required to correct for the
monitor’s non-linearities.
The Metropsis contrast sensitivity system generated luminance
modulated sine gratings (Gabor patches). The orientation of the
stimuli was vertical. The Gabor patches were presented on the
CRT monitor and subtended a visual angle of 4.2. The mean lumi-
nance was used as the background luminance. The Gabor had a
two-dimensional spatial Gaussian envelope and was radially sym-
metrical with equal standard deviations, dx and dy.
Contrast sensitivity functions were determined under both me-
sopic and photopic conditions. Each subject was seated at a fixed
viewingdistanceof 1.5 m fromtheCRTmonitor. Natural pupilswere
used throughout the experiment. The non-dominant eye was oc-
cluded. Testing was carried out in a light free (other than CRT back-
ground mesopic and photopic light) environment. The subject was
dark adapted for 5 min and a 5-min training session was given prior
to testing under mesopic conditions. Subject responses were re-
corded using a handheld responder (CR6, Cambridge Research Sys-
tems Ltd., Cambridge, UK), which communicated with the VSG
device via an infra red link. A four alternate forced choice testing sys-
tem was used, with four possible target locations. The stimuli were
randomly presented at 2 spatial offset from the central cross target.
The subject indicated the location of the target in relation to the fix-
ation cross using the appropriate button on the responder box. The
subject’s contrast sensitivity was determined for five different spa-
tial frequencies (1.0, 4.1, 7.5, 11.8 and 20.7 cpd) under bothmesopic
and photopic conditions, all at amean luminance of 3 cdm2 (meso-
pic) and 100 cdm2 (photopic).
A linear staircase method was used to determine the contrast
threshold. The first Gabor at a particular location was presented
at an initial contrast level where it was anticipated that the obser-
ver would be able to detect the Gabor patch for that particular spa-
tial frequency (initial contrast settings were informed by a brief
pilot study involving five young healthy subjects). Subsequently,
the contrast of the Gabor patch was varied using an adaptive stair-
case procedure, which was computer controlled and depended
upon the subject’s responses. The stimulus contrast was reduced
in steps of 0.3 log units until the subject did not detect the Gabor
patch (first reversal). The contrast was subsequently increased by
0.15-log unit steps until the subject saw the Gabor patch and
responded correctly (second reversal). The Metropsis software
calculated the contrast threshold for each location and spatial fre-
quency by taking the mid-point between the mean for peaks and
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troughs for 12 reversal points. The standard deviation was calcu-
lated by taking the deviations of the peak reversals from their peak
means and using the average square of these deviations to calcu-
late a peak variance. This method was repeated for the troughs.
The square root of both variances were then calculated and aver-
aged to provide the threshold standard deviation.
For each subject, the Metropsis software plotted the inverse of
the contrast threshold against the range of spatial frequencies
tested to provide a contrast sensitivity function under both meso-
pic and photopic conditions.
2.9. Photostress recovery
Photostress recovery time (PRT) was calculated using a macular
automated photostress (MAP) test (Dhalla & Fantin, 2005; Dhalla,
Fantin, Blinder, & Bakal, 2007). MAP is a novel photostress method
for the evaluation of macular function using the Humphrey field
analyzer (Model 745i Carl Zeiss Meditec Inc. Dublin, CA, USA).
The foveal threshold feature of the field analyzer was used to
establish baseline foveal sensitivity as the average of three consec-
utive foveal sensitivity measurements recorded in decibels (dB),
with each dB representing a 0.1 log unit sensitivity variation.
Following baseline foveal sensitivity calculation, the subject was
exposed to aphotostress stimulus,which consistedof a 5-s exposure
to a 300-W, 230-V tungsten lamp head from a viewing distance of
1 m. The spectral irradiance in the wavelength range, 300–800 nm,
was measured using a Bentham DMc 150 double monochromator
scanning spectroradiometer. The input optic consisted of a very high
precision cosine response diffuser (f2 error < 1%) and the measure-
ments were performed in 1 nm intervals. Calibration was carried
out with reference to a quartz-halogen lamp traceable to the UK
National Physical Laboratory. The illuminance at 1 m was obtained
by using the photopic weighting function.
Immediately post-photostress, a continuous and timed cycle of
foveal sensitivity measurements were conducted and recorded for
each subject. The reduction in foveal sensitivity from baseline,
along with the time taken to recover to baseline foveal sensitivity,
was recorded.
2.10. Macular pigment optical density
We used the Macular Densitometer™, a device developed and
originally described by Wooten, Hammond, Land, and Snodderly
(1999), to measure MPOD, including its spatial profile across the
retina (i.e. 0.25, 0.5, 1.0, 1.75 and 3 of retinal eccentricity).
The Macular Densitometer™ uses heterochromatic flicker photom-
etry (HFP) to obtain a valid measure of MPOD at a given retinal
location.(Hammond, Wooten, & Smollon, 2005) This method has
recently been refined and is now referred to as customized HFP
or cHFP. For a detailed description of this protocol please see recent
publications by our research group and others (Loane, Stack,
Beatty, & Nolan, 2007; Nolan et al., 2009; Stringham et al., 2008).
One subject (cwit2553) was excluded from analysis due to inability
to use the Densitometer to obtain reliable MPOD data.
2.11. Fundus photography
Fundus photographs were obtained in both eyes using a NIDEK
non-mydriatic fundus camera (AFC-230). Fundus photographs
were assessed by an expert eyecare professional to exclude fundo-
scopically evident retinal pathology.
2.12. Statistical analysis
The statistical software package SPSS (version 17) and the sta-
tistical programming language R were used for analysis. It was
determined at the outset of the study that a minimum sample size
of 91 subjects was required in order to detect an effect size (corre-
lation between two continuous variables) of 0.4 at the 5% level of
significance with high power. However, 121 subjects were re-
cruited into the study in order to allow for dropouts and for other
possible analyses, in particular repeated measures analysis.
All continuous variables at baseline exhibited a typical normal
distribution. Mean ± SDs are presented in the text and tables.
Comparisons of A and P groups at baseline were conducted using
independent samples t-tests and chi-square analysis, as appropriate.
We conducted repeated measures analysis of MPOD at each ret-
inal eccentricity measured, for each of four study visits using a gen-
eral linear model approach, with treatment (i.e. A and P) and
smoking habits (non-smoker, past and current cigarette smoker)
as between-subjects factors. Where appropriate we used the
Greenhouse–Geisser correction for violation of sphericity. We used
the 5% level of significance throughout our analysis, without
adjustment for multiple testing.
Four visual performance (VP) variables (assessed subjectively
by questionnaire) in this study were recorded as percentage
change of V4 score compared to V1 score. Repeated measures anal-
ysis would not have been appropriate for these, and instead they
were analysed using a general linear model with V4 percentage
change as the dependent variable and fixed between-subjects fac-
tors treatment and smoking habits as explanatory variables.
3. Results
3.1. Baseline findings
The demographic, lifestyle, dietary and serum carotenoid con-
centrations, MPOD, and vision data of all 121 subjects recruited
into the study, and divided by study arm (i.e. A or P group), are
summarized in Table 1. As seen from this table, there was no
Table 1
Demographic, lifestyle, vision, and macular pigment data at baseline.
Characteristic All A P **Sig.
an = 121 n = 61 n = 60
Age 29 ± 7 29 ± 7 29 ± 6 0.864
Body mass index 26 ± 4 26 ± 4 25 ± 3 0.736
Best corrected visual acuity 113 ± 3 113 ± 3 112 ± 3 0.747
Macular pigment optical density
0.25 0.5 ± 0.19 0.49 ± 0.19 0.51 ± 0.20 0.458
0.5 0.4 ± 0.17 0.39 ± 0.16 0.41 ± 0.18 0.425
1 0.22 ± 0.13 0.20 ± 0.12 0.22 ± 0.15 0.433
1.75 0.10 ± 0.11 0.09 ± 0.10 0.10 ± 0.11 0.376
3 0.10 ± 0.10 0.08 ± 0.08 0.12 ± 0.12 0.058
Dietary carotenoids (mg/day)
Lutein 1.26 ± 0.95 1.16 ± 0.96 1.36 ± 0.94 0.253
Zeaxanthin 0.21 ± 0.12 0.19 ± 0.10 0.23 ± 0.14 0.074
Serum carotenoids (lmol/L)
Lutein 0.60 ± 0.32 0.57 ± 0.27 0.62 ± 0.36 0.399
Zeaxanthin 0.36 ± 0.17 0.36 ± 0.15 0.37 ± 0.18 0.623
Sex
Male 69 34 35
Female 52 27 25 0.773
Smoking habitsb
Never smoked 73 42 31
Ex-smoker 21 11 10
Current smoker 27 8 19 0.046
a n = sample size.
b Smoking habits: ex-smoker = smokedP 100 cigarettes in lifetime but none in
last 12 months; current smoker = smokedP 100 cigarettes in lifetime and at least 1
cigarette per week in last 12 months; A = active group and P = Placebo group.
** Sig. = probability significance value.
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significant difference between the A and P groups with respect to
lifestyle, vision, and MP data, with the exception of a statistically
significant difference between these groups for smoking habits
(p = 0.046). Smoking status was therefore considered as a potential
confounding variable and was controlled for throughout repeated
measures analysis. The COMPASS baseline findings have already
been published in a separate manuscript in this journal and, there-
fore, are not discussed in the current manuscript (Loughman,
Akkali et al., 2010).
3.2. Longitudinal findings
3.2.1. Supplement compliance
Seventy-six subjects returned tablets, and (based on the num-
ber of tablets returned) 94.7% of these subjects averaged at least
one tablet per day. The average number of tablets per day was
1.57 in the A group and 1.65 in the P group, a difference that is
not statistically significant (ANOVA, p = 0.32). In comparing change
in MPOD and VP variables between A and P groups, therefore, it
was not deemed necessary to control for differences in compliance
in the two groups.
3.2.2. Macular pigment optical density
We conducted repeated measures ANOVA of MPOD, for all ret-
inal eccentricities measured (i.e. at 0.25, 0.5, 1.0 , 1.75 , and 3),
over time (i.e. over the study period [at V1, V2, V3, and V4, respec-
tively]), using a general linear model approach, with two between-
subjects factors: treatment (A, P) and smoking habits (never, past,
current smoker). As seen in Fig. 1, there was a trend (in the A
group) towards an increase in MPOD at all eccentricities measured,
but this increase was only statistically significant (at the 5% level)
at the more central measured eccentricities (i.e. at 0.25, 0.5 and
1.75).
Fig. 2 (obtained from R statistical program) shows MPOD varia-
tion at 0.25 for 20 consecutive individual subjects from each of the
A and P groups. The graphs are arranged so that those with lowest
MP are in the bottom row, and only subjects who presented for all
four visits are displayed.
3.2.3. Serum concentrations of lutein and zeaxanthin
We conducted repeated measures analysis of serum concentra-
tions of L and Z over time (i.e. over the study period) including all
study visits (V1, V2, V3 and V4), using a general linear model ap-
proach, with treatment and cigarette smoking as between-subjects
factors. As seen in Fig. 3, there was a statistically significant time/
treatment interaction effect for serum concentrations of L, which
remained significant (p < 0.001, for all) using any of the standard
corrections for violation of sphericity. It is clear from the mean
plots of Fig. 3, how these significant time/treatment interaction ef-
fects came about: serum concentrations of L increased with time in
the A group, but remained virtually static in the P group. This time/
treatment effect was significant from V2 (as expected and
confirmed using paired t-test analysis between V1 and V2,
p < 0.001). There was no statistically significant time or time/treat-
ment interaction effect for serum concentrations of Z over the
study period (p > 0.05, for all tests); however, there was a trend to-
wards an increase in the A group.
3.2.4. Visual performance
While the repeated measures ANOVA presented above is based
on findings at all four study visits, it is apparent from the graphs
(Figs. 1 and 2) that the largest differences in MPOD between A
and P subjects are between V1 and V4. The analysis of VP variables
which follows is, therefore, confined to V1 and V4 only (controlling
for between-subjects factors: treatment and smoking habits).
Using repeated measures ANOVA or a general linear model, as
appropriate, we report a statistically significant time/treatment ef-
fect in only one measure of VP, namely ‘‘daily tasks comparative
analysis’’ assessed subjectively (p = 0.03); whereas all other mea-
sures of VP were statistically non-significant (p > 0.05, for all)
[see Table 2].
Fig. 1. Change in MPOD at each eccentricity measured, over the 12-month study period, following supplementation in both the active and placebo groups. Repeated measure
results for MPOD over the four study visits and analyzing visit  treatment interaction at eccentricities 0.25, 0.5, 1.0, 1.75 and 3. The p-values reported are for the
Greenhouse–Geisser correction for violation of sphericity and are as follows: MPOD 0.25 = p < 0.001; MPOD 0.5 = p < 0.001; MPOD 1.0 = 0.001; MPOD 1.75 = 0.585; MPOD
3.0 = 0.103. Subjects were assessed at baseline, 3, 6, and 12 months (V1, V2, V3 and V4, respectively).
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3.2.5. Visual performance differences: low MPOD versus high MPOD
subjects
We investigated whether subjects with high MPOD had signifi-
cantly better VP scores than subjects with low MPOD following
supplementation. We based this investigation, for the most part,
on MPOD at 0.25 at V4. We used tertiles for V4 MPOD at 0.25
eccentricity to create low, medium and high MPOD groups, and
then compared the low and high groups on a variety of VP mea-
sures assessed. The low group consisted of 31 subjects with V4
MPOD at or below 0.46 optical density and the high MPOD group
had 29 subjects with V4 MPOD at or above 0.69 optical density
(Fig. 4). Table 3 presents results for VP measures which differ sig-
nificantly between these low and high MPOD groups. Table 3 also
presents the corresponding results for V1. It should be noted that
differences in these VP measures at V1 were not, in general, statis-
tically significant.
4. Discussion
COMPASS is a randomized placebo-controlled clinical trial of
oral supplementation with a formulation containing the macular
carotenoids (L and Z) and co-antioxidants versus placebo in young
normal subjects The pre-specified hypothesis was that supplemen-
tation, and consequential MPOD augmentation, would result in im-
proved visual performance and/or comfort in those randomized to
the A arm when compared with the P arm, by 12 months.
COMPASS was designed to investigate whether augmentation of
MP results in enhancement of visual performance and/or experi-
ence, regardless of the mechanism(s) whereby any such improve-
ments may be realized. The optical and neuroprotective
hypotheses around MP, which have been discussed previously by
Reading and Weale (1974), later by Nussbaum et al. (1981) and
are extended here, have generated interest amongst macular pig-
ment scientists, evident in a recent review (Loughman, Davison,
Nolan, Akkali, & Beatty, 2010). In brief, some authors have sug-
gested that MP may be important for visual performance and/or
experience by at least one of a number of mechanisms, including
the reduction of the effects of chromatic aberration, light scatter,
higher order aberrations, and plane polarization of light (Loughman,
Davison et al., 2010;Walls & Judd, 1933). Importantly, however, and
in theory at least, the macular carotenoids have the capacity to
confer these optical advantages because of their light-filtering and
dichroic properties and because of their central location within
the retina and crystalline lens.
An additional consideration in relation to any trial investigating
the impact of MP augmentation on visual performance and experi-
ence is the potential beneficial effect of MP on neurophysiological
health. For example, the majority of studies investigating the
effects of MP augmentation in ocular disease, including AMD
Fig. 2. Change in MPOD at 0.25 eccentricity for 20 subjects from each of active and placebo groups. MP 0.25 = macular pigment optical density at 0.25 degrees of
eccentricity
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Fig. 3. Change in serum concentrations of lutein over the 12-month study period,
following supplementation in both the active and placebo groups. Mean (±SD)
serum concentrations of lutein were quantified by high-performance liquid
chromatography at baseline, 3, 6, and 12 months (V1, V2, V3 and V4, respectively)
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(summarized by Loughman, Davison et al. (2010)), have reported a
beneficial effect on vision, and such findings are probably attribut-
able to the neuroprotective, as opposed to the optical, properties of
these intracellular compounds. These studies have traditionally
employed basic psychophysical outcome measures, including vi-
sual acuity and contrast sensitivity, and as such have not included
stimuli likely to reveal improvements facilitated solely by image
enhancement attributable to the optical properties of this pigment.
The study formulation used in COMPASS, in addition to L and Z,
contained the co-antioxidants vitamin C, vitamin E, zinc and sele-
nium. In contrast to the capacity to measure subjects’ retinal re-
sponse to supplementation with the macular carotenoids (i.e. by
measuring MP) it was not possible to assess, or quantify, subjects’
response to supplementation with the above named co-antioxi-
dants. It is important to note that, as seen in the age-related eye
disease study (AREDS) (Kassoff & The AREDS research group,
2001), that these antioxidants may have contributed to any bene-
fits reported in visual performance in the current study.
Interestingly, several studies have reported, amongst normal
subjects, findings which suggest that MP may play a key role in vi-
sual health through a complex interplay between the optical, neu-
rological and physiological mechanisms underlying vision. These
observations include (a) better critical flicker fusion frequency
(CFF) in the presence of higher MPOD (Hammond & Wooten,
2005), (b) associations between high MPOD and crystalline lens
transparency and cataract formation (Brown et al., 1989; Chasan-
Taber et al., 1999; Hammond, Wooten, & Snodderly, 1997), (c)
the presence of L and Z in substantial concentrations in the primary
visual cortex (Craft, Haitema, Garnett, Fitch, & Dorey, 2004) and (d)
higher pattern electroretinogram (PERG) P50 amplitudes and bet-
ter dark adapted cone sensitivities in association with higher
MPOD (Carboni, Forma, Mutolo, Jennings, & Iannaccone, 2010)
(Carboni et al., 2010 ARVO Abstract 1293-A105).
The randomized design of COMPASS resulted in desirable base-
line similarity between A and P groups on possible confounding
variables, with the exception of smoking habits (which was con-
trolled for throughout analysis, as appropriate). Significant efforts
were made to encourage compliance during the study, and based
on the number of tablets returned, we calculated that 95% of sub-
jects averaged at least one tablet per day, with the average number
of tablets consumed per day statistically comparable between the
A and P groups (at around 1.6 tablets per day).
Consistent with the positive tablet compliance, on average, ser-
um L concentrations increased significantly over the course of the
study in the A group with no significant change observed in the P
group. Indeed, despite the slight drop in mean serum L concentra-
tions between V3 and V4 in the A group, L concentrations more
than doubled in the A group over the course of the study. This find-
ing is consistent with other and recent L interventional studies
(Bone & Landrum, 2010; Trieschmann et al., 2007). However, while
average serum L concentrations significantly increased in the A
group and remained stable in the P group, it is important to point
out that 9 (23%) of the A group showed negative or zero change in
serum L concentrations. This ‘‘non-response’’ to L supplementation
in serum is consistent with an observation by Hammond et al. in
1997 who reported that one subject (out of 11 measured) demon-
strated no significant change in serum concentrations of L follow-
ing consumption of 12 mg of L per day over a 15 week study
period (albeit L consumption in that study was achieved from diet
[e.g. spinach and corn] and not from dietary supplements [as in the
current study]). To explain the high percentage of serum non-
response in the current study, we propose the following possibili-
ties: non-compliance with respect to consumption of the study
tablet in these subjects: possible attenuation of the gastrointestinal
absorption of supplemental L and Z if the subject fails to take the
study tablet in the presence of synchronously ingested fat or oil
(importantly, subjects were instructed to consume the daily dose
of two tablets with a meal to facilitate the bioavailability of L from
the tablet). Indeed, it has been shown that the amount of fat in a
person’s diet significantly affects the absorption of L ester and its
bioavailability, and given that the tablet used in the current study
was a film coated tablet not containing oil, failure to consume the
study formulation in the presence of fat and/or oil (i.e. with a meal)
could significantly impact on the bioavailability of L (Roodenburg,
Table 2
Repeated measures assessment of all VP measures in COMPASS.
Visual performance measure Sub-measure/device p-
value
Glare disability Medium glare (Optec)
1.5 cpd 0.58
3.0 cpd 0.94
6.0 cpd 0.65
12.0 cpd 0.96
18.0 cpd 0.49
Glare disability High glare (Optec)
1.5 cpd 0.19
3.0 cpd 0.99
6.0 cpd 0.89
12.0 cpd 0.41
18.0 cpd 0.86
Glare questionnaire Glare comparative analysis 0.32
Glare change analysis 0.88
Glare situational analysis 0.74
Glare subject satisfaction score 0.51
Visual acuity BCVA (Thomson Chart) 0.16
Visual acuity questionnaire Acuity comparative analysis 0.08
Acuity change analysis 0.15
Acuity situational analysis 0.14
Acuity subject satisfaction score 0.59
Daily tasks questionnaire Daily tasks comparative analysis 0.03
Daily tasks change analysis 0.21
Daily tasks situational analysis 0.27
Daily tasks subject satisfaction
score
0.41
Light–dark adaptation
questionnaire
Light–dark comparative analysis 0.35
Light–dark change analysis 0.15
Light–dark situational analysis 0.75
Light–dark subject satisfaction
score
0.56
Mesopic contrast sensitivity F.A.C.T. (Optec)
1.5 cpd 0.72
3.0 cpd 0.77
6.0 cpd 0.84
12.0 cpd 0.66
18.0 cpd 0.5
Mesopic contrast sensitivity Metropsis
1.0 cpd 0.54
4.1 cpd 0.79
7.5 cpd 0.82
11.8 cpd 0.18
20.7 cpd 0.08
Photopic contrast sensitivity Metropsis
1.0 cpd 0.95
4.1 cpd 0.42
7.5 cpd 0.31
11.8 cpd 0.19
20.7 cpd 0.87
Critical flicker fusion frequency Densitometer 0.3
Foveal sensitivity Humphrey perimeter 0.93
VP = visual performance; sig. = probability significance value.
Four VP variables in this study were recorded as percentage change of V4 score
compared to V1 score. Repeated measures analysis would not have been appro-
priate for these, and instead they were analysed using a general linear model with
V4 percentage change as the dependent variable and fixed between-subjects factors
treatment and smoking as explanatory variables.
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Leenen, van het Hof, Weststrate, & Tijburg, 2000). Mean serum
concentrations of Z also increased in the A group, but the increase
was not statistically significant, probably due to the low concentra-
tion of this carotenoid in the study formulation (1 mg/day).
Central MPOD increased significantly in the A group over the
12-month study period and remained stable in the P group. How-
ever, the observed increase in central MPOD in the A group only
became apparent (significantly) at 12 months (whereas, as seen
above, serum concentrations of L were significantly augmented
in the A group at three months). This finding is consistent with pre-
viously published studies reporting slow uptake of L by the retina
(Bone, Landrum, Guerra, & Ruiz, 2003; Johnson et al., 2000), and
inconsistent with others (Connolly et al. (2010)). However, it
should be noted that the retinal uptake in our study was much
slower than any of these previously published studies. For exam-
ple, Bone et al. report that no significant change in MP was seen
until after day 40 following supplementation with L and Z with
up to 30 mg/day of each carotenoid and Johnson et al. report a sig-
nificant increase in MP after 4 weeks of consuming 60 g/day spin-
ach and 150 g/day corn. However, the reason(s) for the difference
seen between studies may be due to any (or a combination of)
the following factors: dose of L and Z consumed per day; type of
L and Z in the supplement (e.g. free versus ester) matrix in which
carotenoids are consumed (e.g. oil versus micro-encapsulated);
whether consumed alone or in the presence of other antioxidants;
poor serum response to the supplement; non-compliance to the
study supplement. Further, and detailed, study on this interesting
topic is merited.
The average increase seen in the A group at 0.5 of retinal eccen-
tricity (the standard and most commonly measured and reported
MPOD eccentricity) over the 12-month study period was
0.11 ± 0.005 optical density, which is comparable to the findings
of Trieschmann et al. who reported an average increase in MP of
0.10 ± 0.009 optical density where they measured MPOD by 2-
wavelength autofluorescence. Interestingly, Trieschmann et al.
used the same study formulation (daily consumption of 12 mg of
L provided as ester) over a 12-month study period as that used
in the current study, but by delivering four tablets per day (each
containing 3 mg of L ester), whereas the current study achieved a
daily consumption of 12 mg of L ester by delivering two tablets
per day (Trieschmann et al., 2007). Unlike the findings reported
by Trieschmann et al., we report that the biggest gain in MPOD
in the A group did not, in general, occur in subjects with lowest
baseline MPOD values. However, consistent with the data reported
by Trieschmann et al., who reported that 20 (21%) of 92 subjects
assessed were retinal non-responders (at 0.5 ), we found that
eight (17%) of the A group at 0.25 and nine (20%) of the A group
at 0.5 showed negative or zero change in MP at 12 months.
In contrast with the MP measures discussed above, the VP mea-
sures assessed in the current study did not, in general, improve sig-
nificantly over time in the A group. This would, superficially at
least, seem to be at odds with the optical and visual health hypoth-
eses of MP’s function. Indeed, it is important to emphasise that, of
all the VP measures assessed, and reported on, in COMPASS (48
variables in total; see Table 2) we report a statistically significant
result for only one measure, namely ‘‘daily tasks comparative anal-
ysis’’, assessed subjectively. It is possible, therefore, as data from
the current study suggest, that supplementation with the macular
carotenoids, and consequential MP augmentation, has no major
impact on visual performance and/or experience in young normal
subjects (our primary research question and the main study
hypothesis). This is, however, at odds with previous reports with
respect to the impact of MPOD augmentation on glare disability
(Stringham & Hammond, 2005, 2008). This discrepancy with ear-
lier findings may be explained, at least partly, by two fundamental
differences between the relevant studies. Firstly, COMPASS was de-
signed to evaluate glare disability under conditions approximating
normal environmental experience. As such, testing was conducted
using natural pupils, which typically constrict under glare condi-
tions, and therefore confer protection against the effects of glare.
The Maxwellian view system employed in other studies does not
Fig. 4. Boxplots of V4 MPOD at 0.25 showing range of values for each tertile group.
MPOD 0.25 at visit 4 = macular pigment optical density at 0.25 degrees of
eccentricity at visit four (12-months) presented for each tertile boxplot. Low,
medium and high boxplots represent low tertile group, medium tertile group and
high tertile groups with respect to MPOD measured at 0.25 degrees of eccentricity.
Black dots represent extreme values (outliers).
Table 3
Comparing visual performance measures between low and high macular pigment optical density groups at visit 4 and visit 1.
Visual performance variable Visit 4 Visit 1
MP groupa Mean (±SD) Sig. MP group Mean (±SD) Sig.
Best corrected visual acuity High 113 (3) High 113 (3)
Low 111 (4) 0.038 Low 112 (3) 0.045
Mesopic CS at 1.5 cpd under high glareb High 28.6 (15.8) High 22.1 (11.6)
Low 21.2 (11.2) 0.042 Low 19.8 (8.2) 0.337
Light/dark adaptation comparative analysisc High 70.3 (17.4) High 62.2 (13.2)
Low 60.6 (13.1) 0.018 Low 60.6 (14.7) 0.624
Mesopic contrast sensitivity at 20.7 cpd O High 54.7 (17.4) High 57.1 (15.0)
Low 62.9 (10.9) 0.035 Low 59.2 (12.1) 0.523
a MP group = macular pigment optical density group tertile for 0.25 eccentricity: high = top tertile, low = bottom tertile.
b Mesopic CS at 1.5 cpd under high glare = night-time contrast sensitivity at low spatial frequencies assessed under high glare conditions.
c Light/dark adaptation comparative analysis = self reported visual performance under changing light conditions compared to friends/family/peers; O = Mesopic contrast
sensitivity at 20.7 cpd = night time contrast sensitivity measured at high spatial frequencies.
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allow normal pupillary response, so, while MP was shown to im-
pact glare disability under these conditions, it is not clear whether
the effect would have remained if a pupillary response had been al-
lowed, which would have caused a variable reduction in retinal
illuminance proportional to the magnitude of the pupillary re-
sponse. Secondly, our findings can only be applied to the stimulus
and glare intensity settings employed here, which, although in-
formed by a detailed pilot study, are less comprehensive than the
variable glare annulus intensity employed by Stringham &
Hammond.
Kvansakul et al. (Kvansakul et al., 2006) conducted a study to
evaluate the effect of MP supplementation on mesopic contrast
acuity thresholds (CAT) in normal subjects.(Kvansakul et al.,
2006) They reported a significant and beneficial effect of MP sup-
plementation on mesopic CAT that was not evident in their placebo
group, their findings therefore appearing to be at odds with those
of the current study, probably reflecting a number of differences
between the two studies in terms of methodology and design
[e.g. stimuli, illumination levels (1cdm2 vs 3cdm2), etc.]. Also,
the design by Kvansakul et al. did not incorporate longitudinal
evaluation of MPOD, which was measured only at the final visit
(interestingly the CATs reported by Kvansakul showed no correla-
tion with MPOD). Furthermore, contrast acuity thresholds were not
measured at baseline, but only after six months of supplementa-
tion and then again at the final 12 month visit. One cannot, there-
fore, draw meaningful conclusions with respect to the relationship,
if any, between their mesopic CAT findings and MPOD, as there is
no record of change in MPOD over their study period. A final point
relates to the sample sizes of the two studies, the investigation by
Kvansakul et al. being based on a placebo group of only five sub-
jects and three groups of subjects receiving supplementation (con-
taining three, five and five subjects respectively) and is thus not
comparable with the COMPASS trial, involving 121 subjects.
There are however, a number of plausible explanations for the
absence of any significant influence of MP augmentation on visual
performance in our study. Firstly, it should be noted that the
majority of study participants exhibited average to high central
MPOD pre-supplementation. Indeed, only a small number of sub-
jects (24%) were found to have central MPOD (at 0.5 eccentric-
ity) less than 0.30 at baseline. Importantly, it has been suggested
previously that MPOD levels greater than 0.30 might be superflu-
ous to visual performance requirements (Reading & Weale, 1974),
due to the non-linear nature of the effect of MP on vision. Fur-
thermore, the increase in MPOD observed in the A group did
not become apparent until the final 12 month visit, and was rel-
atively modest with an average increase of 0.11 ± 0.005 optical
density (at 0.5 eccentricity), and unlike the findings reported
by Trieschmann et al., subjects (in the A group) in the current
study with the lowest MP at baseline did not, in general, demon-
strate the biggest increase in MPOD levels following supplemen-
tation with the study formulation. Indeed, even after 12-months
of supplementation with 12 mg of L per day, over 15% of subjects
in the A group retained central MPOD (at 0.5 eccentricity) values
below 0.3 optical density. In other words, it is possible that the
MP augmentation achieved in the current study was not sufficient
(in an adequate number of subjects) to impact on visual perfor-
mance, and that a greater increase in MPOD, particularly in the
group with lowest baseline MPOD, might be required to elicit
an improvement in visual performance. Also, as mentioned above,
it is also likely that a significant number of subjects in the current
study already had (at baseline) sufficient MP for optimal,
measurable, and appreciable visual performance (i.e. 75% of
subjects in the A group had baseline MP valuesP 0.3 optical
density) and therefore may explain, at least in part, the failure
of the current study to demonstrate an improvement in VP
following supplemental L.
In addition, the nature of the tests employed for visual perfor-
mance testing in COMPASS also merits consideration and discus-
sion. The investigators strategically chose to use tests that were
either typically available in the average consulting room (to ensure
applicability of findings to clinical practice), or designed to repli-
cate typical environmental conditions. As such, most of the tests
did not contain substantial amounts of short wavelength light
maximally absorbed by MP. The typical office or home environ-
ment (where the majority of us spend most of our time), does
not have many short wave dominated light sources. Our results
might, therefore, suggest that subjects’ MP levels pre-supplemen-
tation were sufficient for optimal visual performance in this type
of environment. Our results, therefore, cannot be extrapolated to
short wave dominated visual scenes, such as against the back-
ground of a bright blue sky, which is difficult to replicate in an eco-
logically valid way. Importantly, the changing nature of internal
and device lighting systems, such as the increased use of LED sys-
tems, and xenon car headlights, are extending our exposure to
short wave light sources, and may enhance the applicable rele-
vance of MP for visual performance.
However, given that our study subjects showed an extensive
range of MP values, we considered it meaningful to compare VP
and comfort measures for subjects with high MP (upper tertile)
versus subjects with low MP (lower tertile). We made these com-
parisons at baseline and also at V4. At V1, the subjects in the low
MP group (for central MP at 0.25) were below 0.42 optical density,
whereas subjects in the high MP group (for central MP at 0.25)
were above 0.59 optical density. At V4, the corresponding figures
for low and high groups were 0.46 and 0.67 optical density. Sup-
plementation with L, therefore, appears to have widened the gap
in MP between the lower and upper tertiles. Of interest, at V4 we
report statistically significant differences in some important VP
measures, between lower and upper MP tertile groups, which were
not present at V1.
The most significant finding is that of a 30% greater CS under
high glare conditions in those with highest MPOD following sup-
plementation. Interestingly, of all the tests employed in COMPASS,
the glare source contained the most substantial amount of short
wave light (white LEDs used to generate glare contain a single
‘‘blue’’ peak around 460 nm). These results therefore would seem
to corroborate previous findings which suggest a role for MP in
the attenuation of glare disability (Stringham and Hammond,
2007, 2008; Stringham et al., 2004), and furthermore would seem
to extend those findings to suggest that MP augmentation is ben-
eficial for visual performance under glare conditions, even under
the natural pupil conditions employed here. This finding and
hypothesis is also supported by the results of the visual perfor-
mance questionnaire. Subjects in the A group reported compara-
tively, and statistically significantly, better visual performance for
daily visual tasks (including night driving against oncoming head-
lights). Furthermore, in the tertile analysis, those with the highest
MP reported comparatively, and statistically significantly, better,
capacity to deal with sudden changes in illumination (light/dark
adaptation).
In conclusion, we report that a significant increase in central MP
following L supplementation does not, in general, impact on VP in
young normal subjects, and our pre-specified hypothesis that MP
augmentation would result in improved VP and/or comfort by
12 months, in those randomized to the A arm, remains unproven.
However, subjects with high MP following L supplementation
demonstrate visual benefits with respect to glare disability and
mesopic CS. Further study into MP and its relationship with VP is
warranted to enhance our understanding of this pigment’s role.
However, in order to investigate the impact of MP augmentation
on visual performance, the findings of our study suggest that we
should direct our attention to a) subjects with low baseline central
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MP levels, b) subjects with suboptimal visual performance and c)
subjects with symptoms of glare disability.
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